These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 16790517)
21. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479 [TBL] [Abstract][Full Text] [Related]
22. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965 [TBL] [Abstract][Full Text] [Related]
23. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932 [TBL] [Abstract][Full Text] [Related]
24. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients. Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560 [TBL] [Abstract][Full Text] [Related]
25. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Brana I; Calles A; LoRusso PM; Yee LK; Puchalski TA; Seetharam S; Zhong B; de Boer CJ; Tabernero J; Calvo E Target Oncol; 2015 Mar; 10(1):111-23. PubMed ID: 24928772 [TBL] [Abstract][Full Text] [Related]
26. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. Kosmidis P; Mylonakis N; Nicolaides C; Kalophonos C; Samantas E; Boukovinas J; Fountzilas G; Skarlos D; Economopoulos T; Tsavdaridis D; Papakostas P; Bacoyiannis C; Dimopoulos M J Clin Oncol; 2002 Sep; 20(17):3578-85. PubMed ID: 12202657 [TBL] [Abstract][Full Text] [Related]
27. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409 [TBL] [Abstract][Full Text] [Related]
28. Current and future perspectives in advanced bladder cancer: is there a new standard? von der Maase H Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002 [TBL] [Abstract][Full Text] [Related]
29. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Porter CA; Rifkin RM Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S150-5. PubMed ID: 17562253 [TBL] [Abstract][Full Text] [Related]
30. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090 [TBL] [Abstract][Full Text] [Related]
31. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
32. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group. Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802 [TBL] [Abstract][Full Text] [Related]
33. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Bozionelou V; Vamvakas L; Pappas P; Agelaki S; Androulakis N; Kalykaki A; Nikolaidou M; Kentepozidis N; Giassas S; Marselos M; Georgoulias V; Mavroudis D Br J Cancer; 2007 Jul; 97(1):43-9. PubMed ID: 17551496 [TBL] [Abstract][Full Text] [Related]
34. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P; Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935 [TBL] [Abstract][Full Text] [Related]
36. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA; J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667 [TBL] [Abstract][Full Text] [Related]
37. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma. Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224 [TBL] [Abstract][Full Text] [Related]
38. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232 [TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer. Wong ZW; Ang PC; Chowbay B; Wong NS; See HT; Khoo KS Breast; 2008 Oct; 17(5):517-22. PubMed ID: 18502128 [TBL] [Abstract][Full Text] [Related]
40. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Milano MT; Haraf DJ; Stenson KM; Witt ME; Eng C; Mittal BB; Argiris A; Pelzer H; Kozloff MF; Vokes EE Clin Cancer Res; 2004 Aug; 10(15):4922-32. PubMed ID: 15297392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]